Capsugel Launches LIPIDEX Technology Platform

Capsugel has launched its new LIPIDEX technology platform that integrates its lipid, liquid, and semi-solid fill technologies, product development experience and commercial manufacturing infrastructure. The platform will enable Capsugel’s Dosage Form Solutions (DFS) business unit to accelerate and improve product development for pharmaceutical and nutraceutical customers.
 
The LIPIDEX technology platform centers on Capsugel DFS’ clinical fast-track development program, which utilizes its Lipid Expert System to streamline various aspects of the development process from simple to complex lipid systems in solution, suspension or SEDDS/SMEDDS formulations. Small-scale liquid fill manufacturing technology is also available at the company’s global R&D locations.
 
“Our LIPIDEX technology platform provides tailored solutions for the many challenges our customers face, whether it’s development of low solubility drugs in their pipeline, repositioning existing drugs for better therapeutic performance or rebranding them using innovative dosage forms,” said Amit Patel, president, Capsugel DFS. “Through Capsugel’s historical investments and our recent acquisition of Encap Drug Delivery, the LIPIDEX platform represents the industry’s most comprehensive and vertically integrated offering in the lipid, liquid and semi-solid arena. It spans polymer science and process engineering at the capsule level, as well as API handling, dosage formulation development using expert systems, clinical trial quantity supply and commercial manufacturing.”